Close
A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years
Project Summary
This primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, HIV-1 infected participants aged ≥ 60 years.
Key Project Information
Dates: August 2016 - March 2018 (completed)
UCL lead/Principal Investigator: Dr Laura Waters
Partners: Central and North West London NHS Foundation Trust
Location: Global
Funding: Gilead Sciences
Contact: mmc-research-cnwl@nhs.net
- Research Team
Dr Alejandro Arenas-Pinto
Marzia Fiorino
Dr Lewis Haddow
Dr Sarah Pett